A detailed history of Bridgeway Capital Management, LLC transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 185,109 shares of VYGR stock, worth $992,184. This represents 0.02% of its overall portfolio holdings.

Number of Shares
185,109
Previous 182,831 1.25%
Holding current value
$992,184
Previous $1.45 Million 25.17%
% of portfolio
0.02%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.77 - $9.27 $13,144 - $21,117
2,278 Added 1.25%
185,109 $1.08 Million
Q2 2024

Aug 14, 2024

BUY
$7.42 - $10.54 $22,705 - $32,252
3,060 Added 1.7%
182,831 $1.45 Million
Q1 2024

May 15, 2024

SELL
$7.15 - $10.84 $7,328 - $11,111
-1,025 Reduced 0.57%
179,771 $1.67 Million
Q4 2023

Feb 14, 2024

BUY
$6.28 - $8.81 $1.14 Million - $1.59 Million
180,796 New
180,796 $1.53 Million
Q3 2022

Nov 14, 2022

BUY
$5.57 - $7.47 $83,550 - $112,050
15,000 Added 17.28%
101,781 $603,000
Q1 2022

May 16, 2022

BUY
$2.75 - $9.44 $137,500 - $472,000
50,000 Added 135.94%
86,781 $661,000
Q4 2021

Feb 14, 2022

SELL
$2.47 - $5.55 $358,397 - $805,305
-145,100 Reduced 79.78%
36,781 $100,000
Q3 2021

Nov 15, 2021

BUY
$2.63 - $4.12 $67,278 - $105,393
25,581 Added 16.37%
181,881 $478,000
Q2 2021

Aug 16, 2021

SELL
$3.94 - $5.44 $425,673 - $587,732
-108,039 Reduced 40.87%
156,300 $646,000
Q1 2021

May 17, 2021

BUY
$4.61 - $9.04 $1.22 Million - $2.39 Million
264,339 New
264,339 $1.25 Million
Q4 2018

Feb 14, 2019

SELL
$8.59 - $18.05 $300,650 - $631,750
-35,000 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$17.11 - $21.74 $598,850 - $760,900
-35,000 Reduced 50.0%
35,000 $662,000
Q3 2017

Nov 14, 2017

BUY
$8.37 - $20.59 $585,900 - $1.44 Million
70,000
70,000 $1.44 Million

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $207M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.